Novartis Ag

Claire Adcock

Catherine Leblanc

Nikolaus Johannes Stiefl

Catherine LeBlanc

Robert Alexander Pulz

Maude Nadine Pierrette Pipet

Robin Alec Fairhurst

Urs Baettig

Michael Scott Visser

Peter Hunt

Simone Bonazzi

Artiom Cernijenko

Duncan Shaw

Noel Marie-France Thomsen

Katrin Spiegel

Hasnain Ahmed Malik

Philip Lam

Kathryn Taylor Linkens

The present disclosure provides a compound of Formula (I'): 

3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof

The present invention provides compounds of formula (Ia) and (Ib) which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said compounds and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. 

Substituted pyrrolo[2,3-B]pyrazines for the treatment of disorders and diseases

Substituted pyrrolo[2,3-B]pyrazine compounds and their use

Compounds of formula I in free or salt or solvate form, where T, T, X, R, R, Rand Rhave the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Organic compounds

Compounds of formula (I) in free or salt or solvate form, where T, T, Rand Rhave the meanings as indicated in the specification, are useful for treating inflammatory or obstructive airways, pulmonary hypertension, pulmonary fibrosis, liver fibrosis, muscle diseases and systemic skeletal disorders. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described. 

Pyrimidine derivatives as alk-5 inhibitors

Growing community of inventors

Horsham, United Kingdom

Claire Adcock